Aytu BioScience Provides First Fiscal Quarter 2017 Business Update

Published: Nov 08, 2016

ENGLEWOOD, Colo., Nov. 7, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, provided today an overview of its business and growth strategy, as well as its financial results for the quarter ended September 30, 2016. The Company will host a live conference call and webcast today at 4:30 p.m. ET.

Corporate Highlights:

Successfully launched Natesto® (testosterone) Nasal Gel in the U.S. market

Demonstrated strong Natesto prescription growth, rapidly surpassing previous benchmarks for new and total Natesto prescriptions

Grew the number of unique Natesto prescribers

Showed consistent increases in co-pay coupon redemptions and utilization of proprietary Assure Rx prescription access program

Increased sales and U.S. customer base during the quarter for ProstaScint® (capromab pendetide), the company's proprietary prostate cancer imaging agent

Presented MiOXSYS™ clinical data at the American Society for Reproductive Medicine and the Japanese Society for Reproductive Medicine annual conferences

Back to news